44 Wealth Management LLC Acquires 14,684 Shares of Abbott Laboratories $ABT

44 Wealth Management LLC grew its holdings in Abbott Laboratories (NYSE:ABT) by 498.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,631 shares of the healthcare product maker’s stock after purchasing an additional 14,684 shares during the quarter. 44 Wealth Management LLC’s holdings in Abbott Laboratories were worth $2,361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the business. Cloud Capital Management LLC acquired a new position in Abbott Laboratories in the third quarter valued at approximately $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $31,000. Anfield Capital Management LLC increased its stake in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares in the last quarter. Delos Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories during the 2nd quarter valued at $32,000. Finally, Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories during the third quarter worth $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Mary K. Moreland sold 613 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,055 shares of company stock worth $353,097 in the last ninety days. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $107.99 on Friday. The company has a market capitalization of $187.66 billion, a PE ratio of 29.03, a PEG ratio of 1.72 and a beta of 0.74. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The stock’s 50 day moving average price is $114.58 and its 200-day moving average price is $123.86. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period last year, the business posted $1.34 earnings per share. Abbott Laboratories’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Wall Street Analyst Weigh In

Several research firms have weighed in on ABT. Raymond James Financial decreased their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. BTIG Research decreased their target price on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Weiss Ratings downgraded Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Finally, Piper Sandler cut their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.